Skip to content

Homoeopathic treatment in managing chronic hand eczema patients.

THE EFFECTIVENESS OF INDIVIDUALIZED HOMOEOPATHIC MEDICINE IN MANAGEMENT OF CHRONIC HAND ECZEMA A QUASI-EXPERIMENTAL STUDY. - Nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/07/090030
Enrollment
38
Registered
2025-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20-L30- Dermatitis and eczema

Interventions

Intervention1: Individualized Homoeopathic medicine: Case taking will be conducted using a standard case sheet proforma designed for this study followed by the analysis and evaluation of symptoms. The

Sponsors

Dr.Anjana Krishnan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Participants presenting with symptoms of like erythema ,infiltration ,vesicles, fissures, scaling and edema. Age group between 18-65 years and of any gender.

Exclusion criteria

Exclusion criteria: Participants with psoriasis,Tinea mannum,Lichen planus,Mycosis fungoides,Scabies.. Pregnant and lactating women. Participants with known severe systemic illness, malignancy.

Design outcomes

Primary

MeasureTime frame
Changes in HECSI Score base line 3rd,6th, 9th, 12th month for interpreting the disease activity in hand eczema.Timepoint: At the baseline and at the end of study

Secondary

MeasureTime frame
:Changes in the severity of skin lesion in hand eczema using Quality of life questionnaire of hand eczema-baseline 3rd ,6th ,9th and 12th month .Timepoint: The questionnaires and scales will be administered every 3 rd month from baseline till the end of the study

Countries

India

Contacts

Public ContactDrPDastagiri

National Homoeopathy Research Institute in Mental Health, Kottayam

drdastagirinhrimh@gmail.com9000444409

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026